Flag of the European Union EU Clinical Trials Register Help

Clinical trials for placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44381   clinical trials with a EudraCT protocol, of which   7393   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12,700 result(s) found for: placebo. Displaying page 635 of 635.
    «« First « Previous 627  628  629  630  631  632  633  634  635 
    EudraCT Number: 2008-008447-26 Sponsor Protocol Number: CQAB149B2351 Start Date*: 2009-03-02
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, controlled, parallel group, 12-week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 ...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) SK (Completed) HU (Completed) ES (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2007-007107-32 Sponsor Protocol Number: M10-301 Start Date*: 2009-07-31
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of Carboplatin /Paclitaxel in Combination with ABT-869 Versus Carboplatin/Paclitaxel Alone in Subjects with Advanced or Metastatic Non-S...
    Medical condition: Non small cell lung cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029514 Non-small cell lung cancer NOS LLT
    9.1 10029515 Non-small cell lung cancer recurrent LLT
    9.1 10059515 Non-small cell lung cancer metastatic LLT
    9.1 10029516 Non-small cell lung cancer stage 0 LLT
    9.1 10029517 Non-small cell lung cancer stage I LLT
    9.1 10029518 Non-small cell lung cancer stage II LLT
    9.1 10029519 Non-small cell lung cancer stage III LLT
    9.1 10029520 Non-small cell lung cancer stage IIIA LLT
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV PT
    9.1 10059515 Non-small cell lung cancer metastatic PT
    9.1 10029515 Non-small cell lung cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-001605-14 Sponsor Protocol Number: CCR4309 Start Date*: 2015-07-21
    Sponsor Name:The Royal Marsden NHS Foundation Trust
    Full Title: A Randomised, double-blind, placebo controlled, multi-centre phase II study to assess the Efficacy and safety of 2nd line Olaparib in combination with Paclitaxel, in Western patients with advanced ...
    Medical condition: Advanced Gastric and Gastro-oesophageal cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063916 Metastatic gastric cancer PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017760 Gastric cancer NOS LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017768 Gastric cancer stage IV without metastases LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066350 Adenocarcinoma of the gastrooesophageal junction LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017761 Gastric cancer recurrent PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017766 Gastric cancer stage IV NOS LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061967 Gastric cancer stage IV PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017767 Gastric cancer stage IV with metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-002218-21 Sponsor Protocol Number: 0431-068 Start Date*: 2008-01-03
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Phase III Randomized, Active-Comparator (Pioglitazone) Controlled Clinical Trial to Study the Efficacy and Safety of Sitagliptin and MK-0431A (A Fixed-DOse Combination Tablet of Sitagliptin and M...
    Medical condition: type II diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IS (Completed) IT (Completed) SI (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2008-006049-26 Sponsor Protocol Number: A5271038 Start Date*: 2009-04-29
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 2B/3 OPEN-LABEL ROLLOVER STUDY FOR SUBJECTS DISCONTINUING FROM THE UK-453,061 PROTOCOLS FOR THE TREATMENT OF HIV-1 INFECTED SUBJECTS
    Medical condition: HIV-1
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) PL (Completed) ES (Prematurely Ended) IT (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-003590-24 Sponsor Protocol Number: LPL104884 Start Date*: 2006-03-01
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: LPL104884: A multicenter, randomized, double-blind, placebocontrolled, parallel-group, dose-ranging study of SB-480848, an oral lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, in subje...
    Medical condition: SB-480848 is under developement as a potential anti-atherosclerosis agent for reduction of major cardiovascular events in high risk patient populations.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Completed) EE (Completed) HU (Completed) DE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-003487-48 Sponsor Protocol Number: F373280CA201 Start Date*: 2013-02-25
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.
    Medical condition: F373280 is a new therapy based on DHA delivery (pro-drug) developed for the maintenance of sinus rhythm after electrical cardioversion in persistent atrial fibrillation (AF) patients with chronic h...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed) CZ (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-003640-11 Sponsor Protocol Number: MK0431C-102 Start Date*: 2008-10-30
    Sponsor Name:MERCK & CO., INC.
    Full Title: A Multicenter, Randomized, Double-Blind Study of the Co-Administration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control.
    Medical condition: Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049746 Insulin-requiring type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SI (Completed) AT (Completed) LT (Completed) EE (Completed) LV (Completed) GR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-001487-67 Sponsor Protocol Number: A8311003 Start Date*: 2007-10-24
    Sponsor Name:Pfizer Limited, Ramsgate Road, Sandwich, Kent, UK
    Full Title: A PARALLEL-GROUP, RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER DOSE RESPONSE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF- 00885706, A 5-HT4 RECEPTOR PARTIAL AGONIST, AS ADD-ON THERAPY TO ESOMEPRAZOLE...
    Medical condition: GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018203 GERD LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) ES (Completed) BE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2007-005220-33 Sponsor Protocol Number: D1690C00004 Start Date*: 2008-02-08
    Sponsor Name:AstraZeneca AB
    Full Title: A 52-Week, International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III study with a 156-Week Extension Period to Evaluate the Efficacy and Safety of Dapaglif...
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029505 Non-insulin-dependent diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed) FR (Completed) NL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001857-29 Sponsor Protocol Number: V130_14 Start Date*: 2019-03-13
    Sponsor Name:Seqirus UK Limited
    Full Title: A Phase III, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus' Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to...
    Medical condition: Prophylaxis of influenza virus infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BG (Completed) EE (Completed) CZ (Completed) LV (Completed) PL (Completed) Outside EU/EEA RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2010-024540-15 Sponsor Protocol Number: C38072/3085 Start Date*: 2011-07-20
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: An Open-Label Extension Study to evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients with Eosinophilic Asthma who completed a prior Cephalon-sponsored Stu...
    Medical condition: Treatment for patients with eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) SE (Completed) CZ (Completed) GR (Completed) HU (Completed) NL (Completed) DK (Prematurely Ended) PL (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2009-016375-30 Sponsor Protocol Number: MK-0462-086 Start Date*: 2010-02-16
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Worldwide, Open Label, Clinical Trial to Examine the Long Term Safety and Tolerability of Rizatriptan in Pediatric Migraineurs for the Treatment of Migraine With or Without Aura
    Medical condition: Long term treatment of acute migraine, with or without aura, in children and adolescents, ages 12 to 17 years.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10066635 Acute migraine LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed) DE (Completed) BE (Completed) ES (Prematurely Ended) EE (Completed) LV (Prematurely Ended) SE (Completed) FR (Prematurely Ended) PL (Prematurely Ended) DK (Completed) NO (Completed) GB (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-022872-30 Sponsor Protocol Number: PALO-10-20 Start Date*: 2011-08-04
    Sponsor Name:Helsinn Healthcare SA
    Full Title: A multicenter, randomized, double-blind, parallel group study to evaluate the efficacy and safety of two different doses of palonosetron compared to ondansetron in the prevention of CINV in pediatr...
    Medical condition: Study to evaluate the efficacy and safety of two different doses of palonosetron compared to ondansetron in the prevention of CINV in pediatric patients undergoing single and repeated cycles of MEC...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10042613 - Surgical and medical procedures 10049091 Chemotherapy antiemetic prophylaxis LLT
    13.1 10042613 - Surgical and medical procedures 10036899 Prophylaxis against chemotherapy induced vomiting LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) AT (Completed) BG (Completed) EE (Completed) DE (Completed) FR (Ongoing) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-001059-39 Sponsor Protocol Number: P 04103 Start Date*: 2005-11-10
    Sponsor Name:Schering-Plough Research Institute
    Full Title: A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting with...
    Medical condition: Primary Hyperlipidermia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10016205 Familial hyperlipidaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DK (Completed) SE (Completed) ES (Completed) BE (Completed) CZ (Completed) IT (Completed) DE (Completed) GB (Completed) AT (Completed) PT (Completed) SK (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004076-38 Sponsor Protocol Number: 511.118 Start Date*: 2007-11-30
    Sponsor Name:Boehringer Ingelheim France
    Full Title: A Twenty Eight –Week, Open-Label, Safety Study of Flibanserin 50 milligrams to 100 milligrams dailyin Premenopausal European Women With Hypoactive Sexual Desire Disorder
    Medical condition: Primary generalized acquired Hypoactive Sexual Desire Disorder in Premenopausal women
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020933 Hypoactive sexual desire disorder LLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed) NL (Completed) FI (Completed) BE (Completed) ES (Completed) CZ (Completed) SE (Completed) GB (Completed) AT (Prematurely Ended) HU (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016648-38 Sponsor Protocol Number: C10953/3074 Start Date*: 2010-08-06
    Sponsor Name:Cephalon, Inc.
    Full Title: A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With ...
    Medical condition: Major Depression Associated With Bipolar I Disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) BG (Prematurely Ended) ES (Completed) DE (Prematurely Ended) FI (Completed) SK (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016178-33 Sponsor Protocol Number: 1245.25 Start Date*: 2010-11-12
    Sponsor Name:Boehringer Ingelheim B.V.
    Full Title: A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in ...
    Medical condition: The study will be performed in patients with type 2 diabetes mellitus and high cardiovascular risk who have insufficient glycaemic control despite diet and exercise and are either treatment naïve o...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) ES (Completed) BE (Completed) FR (Completed) IT (Completed) HU (Completed) PT (Completed) GB (Completed) AT (Completed) GR (Completed) PL (Completed) EE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2008-001805-40 Sponsor Protocol Number: PGL07-022 Start Date*: 2008-07-28
    Sponsor Name:PregLem S.A.
    Full Title: A Phase III, randomised, parallel group, double-blind, double-dummy, active comparator -controlled, multi-center study to assess the efficacy and safety of PGL4001 (ulipristal) versus GnRH-agonist ...
    Medical condition: Uterine myomas are benign, monoclonal, hormone sensitive, smooth muscle tumors of the uterus. It is the most common tumor of the female reproductive tract in pre-menopausal women and mostly asympt...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10046801 Uterine myoma LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) ES (Completed) AT (Completed) FR (Completed) IT (Completed) PL (Completed) DE (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000374-37 Sponsor Protocol Number: 161505 Start Date*: 2016-10-28
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculone...
    Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DK (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) NO (Completed) GR (Completed) SK (Prematurely Ended) DE (Completed) PL (Completed) HR (Completed) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 627  628  629  630  631  632  633  634  635 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Feb 13 13:23:31 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA